Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) Director David Baltimore purchased 19,610 shares of Regulus Therapeutics stock in a transaction on Thursday, January 30th. The stock was bought at an average price of $1.06 per share, with a total value of $20,786.60. Following the transaction, the director now owns 22,169 shares of the company's stock, valued at approximately $23,499.14. This represents a 766.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Regulus Therapeutics Stock Performance
Shares of Regulus Therapeutics stock traded up $0.11 during trading hours on Tuesday, hitting $1.34. The company's stock had a trading volume of 3,802,677 shares, compared to its average volume of 774,939. Regulus Therapeutics Inc. has a 12-month low of $0.83 and a 12-month high of $3.79. The business has a 50 day moving average price of $1.45 and a two-hundred day moving average price of $1.53. The company has a market cap of $87.77 million, a PE ratio of -1.25 and a beta of 1.58.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Regulus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.80.
Check Out Our Latest Analysis on RGLS
Hedge Funds Weigh In On Regulus Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning purchased a new stake in Regulus Therapeutics in the 3rd quarter worth $26,000. SG Americas Securities LLC bought a new stake in shares of Regulus Therapeutics in the third quarter worth about $33,000. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter worth about $46,000. JPMorgan Chase & Co. lifted its position in shares of Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock worth $124,000 after buying an additional 52,059 shares in the last quarter. Finally, Barclays PLC boosted its stake in Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after buying an additional 62,549 shares during the last quarter. Institutional investors own 92.38% of the company's stock.
Regulus Therapeutics Company Profile
(
Get Free Report)
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Further Reading
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
